A self-assembled peptide was discovered in 1992 by Dr. Shuguang Zhang of MIT. Our company is globally developing businesses based on various rights associated with self-assembling peptide technology licensed from MIT.
Signed material transfer agreements (MTAs) with over 100 research institutions and universities.
Exploring new uses globally with the peptide platform technology.
In addition to surgical treatment, which is already being commercialized, we are also conducting R&D in the huge markets of regenerative medicine and DDS.
|With a focus on Purestat, which has the strength not only in hemostasis but also in overall strength, we are developing postoperative bleeding materials, mucous membrane lifting-up solutions, vascular embolization materials and so on.
|We are developing products for radiation proctitis (RP), inflammatory bowel disease (IBD), wound healing in the field of cosmetic surgery, and bone and heart muscle regeneration.
|Based on the DDS technology to make the required drug act at the required site for the required length of time, we are promoting the delivery of nucleic acid drugs for cancer and malignant pleural mesothelioma.